GB2144419A - Azetidinones - Google Patents

Azetidinones Download PDF

Info

Publication number
GB2144419A
GB2144419A GB08419149A GB8419149A GB2144419A GB 2144419 A GB2144419 A GB 2144419A GB 08419149 A GB08419149 A GB 08419149A GB 8419149 A GB8419149 A GB 8419149A GB 2144419 A GB2144419 A GB 2144419A
Authority
GB
United Kingdom
Prior art keywords
group
general formula
compound
substituted
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08419149A
Other versions
GB2144419B (en
GB8419149D0 (en
Inventor
Paolo Lombardi
Maristella Colombo
Angelo Crugnola
Giovanni Franceschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Publication of GB8419149D0 publication Critical patent/GB8419149D0/en
Publication of GB2144419A publication Critical patent/GB2144419A/en
Application granted granted Critical
Publication of GB2144419B publication Critical patent/GB2144419B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

<IMAGE> Azetidinones of the above formula (R1=H or a group which can be replaced by H in a single step reaction proceeding under mild conditions, R2=H or a hydroxy protecting group, R3= substituted or unsubstituted alkyl or aryl, R4=H, lower alkyl, phenyl, or substituted phenyl) are useful intermediates in the preparation of penems. Their preparation is also described.

Description

SPECIFICATION Azetidinones The invention relates to chiral azetidinones and to a stereoselective process for their preparation. The azetidinones according to the invention are useful as intermediates for the preparation and known and new p-lactam compounds, including 8R,6S,5R penems having the general formula I
wherein R represents an organic group as described in British Patent Specifications Nos. 2043639 and 2013674 and in German Patent Specification No. 2819655. Such penems have shown high antibacterial activity.
In this Specification, the term "lower alkyl" means a straight or branched chain alkyl group having from 1 to 4 carbon atoms. Functionalized terms, such as "lower alkoxy" and "lower haloalkyl" are to be interpreted correspondingly.
The term "hydroxy protecting group" means any group conventionally used for the protection of a hydroxy function during chemical reactions. Such groups include, but are not limited to, lower alkoxycarbonyl groups such as t-butoxycarbonyl; lower haloalkoxycarbonyl groups such as 2 iodethoxycarbonyl or 2,2,2-trichloroethoxycarbonyl; optionally substituted aralkoxycarbonyl groups such as benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl and p-nitrobenzyloxycarbonyl; tri-(lower alkyl)-silyl groups such as t-butyldimethylsilyl ortrimethylsilyl; tertiary alkyl groups having from 4 to 10 carbon atoms such as t-butyl; substituted or unsubstituted mono-, di- or tri-phenylmethyl groups such as benzyl, p-methoxybenzyl, diphenylmethyl, di-(p-methoxyphenyl)-methyl, p-methoxyphenyl, zx,4- dimethoxybenzyl and trityl groups; and substituted or unsubstituted phenyl groups such asp- methoxyphenyl.
The term "a carboxy protecting group" means any group conventionally used for the protection of a carboxy funtion during chemical reactions. Such groups include, but are not limited to, lower alkyl groups such as methyl, ethyl, isopropyl and t-butyl; lower haloalkyl groups such as 2-iodoethyl and 2,2,2trichloroethyl; lower alkoxymethyl groups such as methoxymethyl, ethoxymethyl and isobutoxymethyl; lower alkoxycarbonyloxy methyl groups such as acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl; 1- (lower alkoxycarbonyloxy)-ethyl groups such as 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl; optionally substituted arylmethyl groups such as benzyl,p-methoxybenzyl, o-nitrobenzyl and p-nitrobenzyl; benzhydryl; phthalidyl; and tri-(lower alkyl)-silyl groups such as trimethylsilyl and t-butyldimethylsilyl.
The invention provides chiral azetidinones having the general formula Il
1'R*,3R*,4R* 1' R*,3R*, 4S* wherein R1 represents a hydrogen atom or a group which can be replaced by a hydrogen atom in a single step reaction proceeding under mild conditions, R2 represents a hydrogen atom or a hydroxy protecting n, R3 represents a substituted or unsubstituted alkyl or aryl group and R4 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted phenyl group.
Groups which R1 represent include (i) unsubstituted or substituted phenyl groups, especially those of-the formulae
(ii) unsubstituted or substituted benzyl groups, especially those of the formulae
(iii) unsubstituted or substituted benzyloxy groups, especially benzyloxy and p-nitrobenzyloxy groups, (iv) trisubstituted being alkyl, aryl or aralkyl groups, especiallytrimethylsilyl, dimethyl-t-butyl-silyl and diphenyl-t-butyl-silyl groups, and (v) groups of the formulae
wherein each R5 independently represents a hydrogen atom, a trialkylsilyl group, a lower alkyl group (especially methyl or ethyl) or an acyl group (especially acetyl or trifluoroacetyl).
Groups which R2 may represent include alkoxycarbonyl groups, for example t-butoxycarbonyl; halogen substituted lower alkoxycarbonyl groups, for example 2-iodoethoxycarbonyl or 2,2,2 trichioroethoxycarbonyl; optionally substituted aralkoxycarbonyl groups, for example benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl or p-nitrobenzyloxycarbonyl; a tri-(lower alkyl) silyl group, for example t-butyl-dimethylsilyl or trimethylsilyl; a tertiary alkyl group having from 4 to 10 carbon atoms, for example t-butyl; a substituted or unsubstituted mono-, di- ortriphenylmethyl group, for example benzyl, p-methoxybenzyl, diphenylmethyl, di-(p-methoxyphenyl)-methyl, p-methoxyphenyl, or,4- dimethoxybenzyl or trityl; or a substituted or unsubstituted phenyl group, for example p-methoxyphenyl.
R3 preferably represents a methyl group. The preferred lower alkyl groups which R4 may represent are methyl and ethyl; the preferred substituted phenyl groups which R4 may represent arep-nitrophenyl and p-chlorophenyl.
The compounds according to the invention contain asymmetrical carbon atoms in their structures and, therefore, may exist in optical isomers as well as steric isomers. It is a purpose of the present invention to disclose a process to make preferentially one steric isomer only, which may exist as a single enantiomer or as a racemic mixture.
Such enantiomers are represented herein by a single chemical structure for simplicity, but the present invention includes within its scope each anantiomer as well as a racemic mixture thereof. The prefixes R* and S* (said R star and S star) are used in this Specification to designate a chiral compound with an univocally determined relative configuration (steric isomer) in one and/or the other mirror image (enantiomer) singularly described by the relative sequence of the prefixes. However, the enantiometers having the-R configuration at C-1' are preferred.
The chiral azetidinones II may be prepared by simple chemical manipulations of chiral compounds having the general formula lil
1'R*,3R*,4S* wherein R1, R2 and R3 are as above defined, X represents a halogen atom and A represents an organic group.
The preferred halogen atoms which X may represent are chlorine, bromine and iodine. The preferred organic groups which A may represent include (i) a carboxy group, (ii) a group of the general formula COOR6wherein R6 represents a carboxy protecting group, (iii) a group of the general formula COR4 wherein R4 is as above defined, and (iv) a group of the general formula R7 wherein R7 represents a straight or branched chain substituted or unsubstituted alkyl group; a substituted or unsubstituted mono-, di- ortriphenylmethyl group, for example benzyl; an alkoxy or aryloxy group; an alkylthio or arylthio group; a protected acyl group, for example phenyl-ethylidene or substituted phenylethylidene; and a group of the general formula
wherein R4 is as above defined.
We have surprisingly found that the compounds lil may be obtained by the stereospecific cycloaddition of a chiral a-haloalkylketene having the general formula IV (or a suitable precursor thereof)
R,S wherein R2 represents a hydroxy protecting group and P3 and X are as above defined, to a Schiff base or imine derivative having the general formula V
wherein A represents a group COOR6, COR4 or R7 as above defined and wherein R, represents a group which can be replaced by a hydrogen atom in a single step reaction proceeding under mild conditions.
The cycloaddition proceeds such that the compounds Ill have the two chiral centres at C-3 and C-4 univocally commanded by the configuration of the starting chiral ketene IV. If the starting chiral ketene IV is a racemic mixture, described by the prefix (R,S), only one diastereoisomeric azetidinone is formed, therefore the cycloaddition is said to be diastereoselective and the product is designated by the prefixes R* and S*. If the starting chiral ketene IV is an enantiomer, described by either the prefix R or S, only one enantiomeric azetidinone is formed, therefore the cyloaddition is said to be enantioselective and the product is designated by the prefixes R or S.
Since pharmacologically active 8R,6S,5R penems I may be obtained from azetidinones II having the 1 'R,3R,4RS configuration, by known reactions and methods as described, inter alia, in our German Patent Specification No. 3245270, the process of the invention is very useful in providing optically active azetidinones which are key intermediates in the synthesis of biologically active penems. Although a number of similar cycloadditions to give azetidinones have been reported, none leads to total aymmetric induction, therefore the cycloaddition process of the invention is surprisingly advantageous.In accordance with the process of the invention a starting chiral ketene IV having the R configuration will lead univocallyto azetidinones II having either the 1'R,3R,4R configuration or the 1'R,3R,4S configuration, so providing a novel and practical route to pharmacologically active penems. Moreover, the compounds Ill and some compounds II are new.
The process of the invention is illustrated by the following reaction scheme.
Step (a) of the process comprises reacting a chiral ketene IV with a Schiff base or imine V. The chiral ketene IV is best generated from a suitable chiral acyl derivative of the general formula IVa, wherein X, R2 and R3 have the meanings given above for the ketenes IV and Y represents a halogen atom, preferably a chlorine or bromine atom, or a conventional carboxy activating group. Suitable carboxy activating groups include groups such as acetoxy, trifluoroacetoxy and pivaloyloxy; alkoxy-groups; and groups having the formulae
The chiral acyl derivatives IVa may be prepared from the corresponding free carboxylic acids by methods well known to the skilled chemist.
The Schiff bases or imine derivatives V may be prepared from an aldehyde derivative and a primary amine in a conventional manner, or by other methods well known to the skilled chemist, according to the substitution pattern on the compounds V.
The first step of the process is a 2 + 2 cycloaddition reaction between the a-haloalkyl ketene IV and the imine V to form the azetidinone III wherein, at this stage A, R1, R2 and P3 have the meanings given above for the compounds IV and V. The reaction conditions for the cycloaddition may vary in accordance with the substitution pattern in the acyl derivative IVa. The cycloaddition is carried out in presence of a base such as triethylamine, pyridine, lutidine, N,N-dimethyl-pyridine or DBU in an inert organic solvent such as a hydrocarbon, aromatic hydrocarbon, halogenated hydrocarbon, ether, dimethylsulphoxide, dimethylformamide or a mixture thereof. The reaction temperature may be from -30"C to 100 C and the reaction may take from 30 minutes to 24 hours.
Step (b) of the process comprises the reductive dehalogenation of the compound Ill to give a compound having the general formula VI. This is done such that the proton replacing the halogen X occupies the spatial position occupied by the halogen in the compound lil, thus maintaining the same configuration at C-3 of the compound VI, albeit the description of this chiral centre will change from R* to S+, as well as the description of the chiral centre at C-4 from S* to R*, due to the change in the priority sequence according to the universally accepted Cahn, Ingold and Prelog rules.
The reductive dehalogenation may be carried out by catalytic hydrogenation, reduction with metal hydrides, or reduction with an active metal or alloy in a protic medium. The reductive dehalogenation may be performed on the compound III for any of the meanings previously defined for R1, R2 and A. In particular, when R1 is hydrogen, R2 is hydrogen or A is a carboxy group, extra steps are necessary to have these groups before proceeding to step (b). Such transformations are easily performed by resorting to simple chemical reactions well known to the skilled in the art.The preferred method for conducting step (b) of the process is to stir a solution or a suspension of the compound III in an organic solvent such as benzene, toluene or dimethylsulphoxide with tributyltinhydride at a temperature ranging from 0 C to 1 OO"C, for from 10 minutes to 24 hours.
Step (c) of the process comprises transforming the compound VI into the azetidinyl carboxylate II, and this may be performed on the compound VI for any of the meanings previously defined for R1 and R2. Since this step comprises an oxidative degradation of the group A, A should only represent a carboxy group or the group COR4. If such meanings have not been previously introduced in the compound III prior to step (b), extra steps are needed to have these groups before proceeding to step (c). Such transformations are easily performed by resorting to simple chemical reactions well known to the skilled chemist.
Particularly, when A represents a carboxy group, the oxidative degradation is carried out in the form of an oxidative decarboxylation, preferably with lead tetraacetate. The oxidative decarboxylation can be performed by treating the compound VI with an amount of not less than 1 mole of lead tetraacetate, preferably 1 to 3 mole per mole of the compound VI in an inert solvent in the presence or absence of a base, such as pyridine or lutidine, or a salt, such as sodium acetate or potassium acetate. Examples of suitable inert solvent are hydrocarbons, aromatic hydrocarbons, acetic acid, dimethylformamide, dimethylsulphoxide, pyridine, HMPA, diethyl ether, tetrahydrofuran, dioxan, or a mixture thereof. The reaction temperature can be from 00C to 100 C, and the reaction time from 10 minutes to 24 hours. In this case, one obtains inversion of configuration at C-4, therefore the compound II, wherein R4 is methyl, is described as 1 'R*,3R*, 4R*.
When A represents the group COR4, the oxidative degradation is carried out in the form of the Baeyer-Villiger reaction. This conversion can be performed by treating the compound VI with an oxidant agent such as a solution of peracetic acid in acetic acid containing sulphuric acid orp-toluenesulphonic acid as a catalyst, solutions of peroxytrifluoroacetic, monopermaleic, monoperphthalic or perbenzoic acids in methylene dichloride, chloroform or ethyl acetate, peroxymonosulphuric acid or mixture of hydrogen peroxide with an acid or a base or hydrogen peroxide-hexafluoroacetone adduct, inorganic oxidant salt such as ceric ammonium nitrate in acetonitrile and water. The reaction may be carried out at from- 100C to 100 C, for a period of from 30 minutes to 72 hours.In this case one obtains retention of configuration at 0-4, therefore the compound of general formula (II) is described as 1 'R*,3R*,4S*.
The steps (d) and (e) constitute an alternative route to the compound II where the oxidative degradation at C-4, as described in the step (c) is performed prior to the reductive dehalogenation at C-3, as described in the step (b). In this case the intermediate compound of the general formula VII has the configuration 1'tri, 'R*,3S*, 4S* or 1 'R*,3S,4R* according to the meaning of A, that is the form of oxidative degradation adopted.
The following Examples illustrate the invention.
EXAMPLE1 1-p-methoxyphenylJ-{3R*J-3-bromo-31, 1'-[(1 'R*)-t-butyldimethylsllyloxy]-ethyJ}-(4S*)-4-methoxycarbonyl- azetidin-2-one
A solution of 15 mmol of (2R*)-2-bromo-(3R*)-3-(t-butyidimethylsilyloxy)-butyryl chloride in 20 ml of dry benzene was added over a period of 3 hours under nitrogen at 0 C to a stirred solution of 1.93 g (10 mmol) of p-methoxycarbonylmethyleneamino-anisole and 3.5 ml (25 mmol) of triethyiamine in 25 ml of dry benzene.
The reaction mixture was stirred for a further 1 hour and was then washed with an aqueous solution of sodium chloride, 1 N hydrochloric acid, a saturated aqueous solution of sodium bicarbonate and an aqueous solution of sodium chloride in that order. The washed reaction mixture was then dried over anhydrous sodium sulphate and filtered. The benzene was evaporated off in vacuo to give 4 g of an oily residue which was purified by column chromatography over 150 g of silica gel. Elution with hexane:ethyl acetate 93.7 by volume gave the title compound as an oil (2.4 g, 50% yield).
I.R. (CHCI3,cm-1): 1765,1510 N.M.R. (CDC13, 6): 0.10 (3H, s) 0.13 (3H, s) 0.81 (9H,s) 1.50 (3H, d, J = 6 Hz) 3.77 (3H, s) 3.82 (3H, s) 4.30 (1H, q, J = 6 Hz) 4.85 (1 H, s) 6.8-7.3 (4H, ABq, J = 10 Hz) EXAMPLE 2 1-(p-methoxyphenyl)-(3R*)-3-{ 1'-[(1'R*J-t-butyl-dimethylsilyloxyl-ethyls-(4R*J-4methoxycarbonyl-azetidin- 2-one
A mixture of 950 mg (2 mmol) of the compound prepared in Example 1,0.64 ml (2.4 mmol) oftributyltin hydride and 10 mg of AIBN was refluxed for 1 hour in 80 ml of dry benzene.The cooled reaction mixture was thoroughly washed with water and an aqueous solution of sodium chloride, dried over anhydrous sodium sulphate, filtered off and evaporated to dryness in vacuo to give the crude title compound as a fairly pure oil (755 mg. 96%).
I.R. (CHC13, cam~1): 1755, 1510 N.M.R. (CDCI3, S):0.02 (3H, s) 0.10 (3H, s) 0.87 (9H, s) 1.40 (3H, d, J = 6 Hz) 3.56 (1 H, collapsed dd, J = 6 Hz) 3.78 (6H, s) 4.20-4.60 (1 H, m, J = 6 Hz) 4.60(1H,d,J = 6 Hz) 6.80-7.30 (4H, ABq, J = 10 Hz) EXAMPLE 3 1-(p-methoxyphenyl)-(3R*)-34 1'-[(1'R*)-t-butyldimethyl-silyloxyl-ethyl}-(4R*)-4-carboxy-azetidin-2-one
A mixture of 755 mg of the crude compound prepared in Example 2,2 ml of pyridine and 4 ml of 0.5 N aqueous sodium hydroxide solution was stirred at ambient temperature for 24 hours. The reaction mixture was then cooled, carefully acidified with concentrated hydrochloric acid and extracted with ethyl acetate (3 x 20 ml).The combined extracts were washed with an aqueous solution of sodium chloride, dried over anhydrous sodium sulphate and evaporated in vacuo to give the crude title compound as a gum (585 mg, 82%).
I.R. (CHCl3,cm-1). 3600-2400.1755,1725,1510 N.M.R. (CDCI3,8):0.06 (6H, s) 0.83 (9H, s) 1.37 (3H, d, J = 6 Hz) 3.60 (lH,dd,J = 6 Hz) 3.74 (3H, s) 4.20-4.60 (1 H, m, J = 6 Hz) 4.60 (1h, d,J = 6 Hz) 6.80-7.30 (4H, ABq, J = 10 Hz) 9.80 (1 H, br s) EXAMPLE 4 1-(p-methoxyphenyl)-(3R*)-3{ 1'-[(1'R*]-t-butyldimethyl-silyloxy}-(4R*)-4-acetoxy-azetidin-2-one
A mixture of 240 mg (0.63 mmol) of the compound prepared in Example 3,017 ml (1.9 mmol) of anhydrous pyridine and 620 mg (1.26 mmol) of 90% lead tetraacetate was stirred in 10 ml of dry benzene at 50 C for 30 minutes. The cooled reaction mixture was filtered through 2 g of florisil, washing with an additional 30 ml of benzene.The combined benzene solutions were washed with 1N hydrochloric acid and with an aqueous solution of sodium sulphate, dried over an hydros sodium sulphate and filtered. Evaporating off the benzene in vacuo gave the crude title compound as a fairly pure oil (210 mg, 85%).
I.R. (CHCI3, cm-5): 1755, 1510 N.M.R. (CDCl3, b) :0.07 (6H, s) 0.75 (6H, s) 1.31 (3H, d, J = 6 Hz) 2.10 (3H,s) 3.18(1H,d,J = 3 Hz) 3.75 (3H, s) 4.10-4.40(1H,m,J = 3Hz, 6Hz) 6.60 (1 H, s) 6.78-7.35 (4H, ABq, J = 10 Hz) EXAMPLE 5 (3R*)-3{ 1'[1'R*)-t-butydimethylsilyloxy]-ethyl}-(4R*)-4-acetoxy-azetidin-2-one
A solution of 3.84 g (7 mmol) of ceric ammonium nitrate in 25 ml of water was added over a period of 2 hours at -10 C to a solution of 920 mg (2.3 mmol) of the compound prepared in Example 4 in 25 ml of acetonitrile. The reaction mixture was stirred for a further 1 hour at - 1 00C and then diluted with 50 ml of water.It was then extracted 3 times with 30 ml aliquots of ethyl acetate, and the combined extracts were washed with a saturated aqueous solution of sodium bicarbonate, five times with 30 ml aliquots of a 10% aqueous solution of sodium sulphite, with 30 ml of saturated aqueous sodium bicarbonate and with an aqueous solution of sodium chloride in that order. The washed solution was dried over anhydrous sodium sulphate and filtered. The solvent was evaporated off in vacuo to give the crude title compound as a fairly pure white solid (560 mg,85%).
I.R. (CHCI3, cm-1): 3420, 1780, 1745 N.M.R. (CDCl3, b):0.06 (6H, s) 0.84 (9H, s) 1.25 (3H, d, J = 6 Hz) 2.10 (3H, s) 3.15(lH,d,J = 3 Hz) 4.08-4.33 (1 H, m, J = 3 Hz, 6 Hz) 5.82 (1 H, s) 6.78 (1 H, br s) EXAMPLE 6 1-(p-methoxyphenyl)-(3R*)-3-bromo-{1'-[1'R*)-t-butyl-dimethyilsilsyloxy)-ethyt}-(4S*)-4-p-chlorobenzoyl)azetidin-2-one
A solution of 7 mmol of (2R*)-2 bromo-(3R*)-3-(t-butyl-dimethylsilyloxy)-butyryl chloride in 10 ml of methylene dichloride was added over a period of 2 hours under nitrogen at 0 C to a stirred solution of 1.38 g (5 mmol) of 4-(p-chlorobenzoylmethyleneamino)-anisole and 1.75 ml (12.5 mmol) oftriethylamine in 15 ml of dry, methanol free methylene dichloride. The reaction mixture was then washed with water, IN hydrochloric acid, water, a saturated aqueous solution of sodium bicarbonate and water in that order. The washed reaction mixture was then dried over anhydrous sodium sulphate and filtered. The methylene dichloride was evaporated off in vacuo to give 3.16 g of an oily residue which was purified by column chromatography over 120 g of silica gel. Elution with hexane:ethyl acetate 93:7 by volume gave the title compound as a foam (2.35 g, 85% yield).
i.R. (CHCI3, cm-1): 1765, 1690,1590,1510.
N.M.R. (CDCI3, b):0.17 (6H, s) 0.88 (9H, s) 1.50 (3H, d, J = 6 Hz) 3.73 (3H, s) 4.48(1H,q,J =6Hz) 5.72 (1 H, s) 6.70-8.10 (8H, 2ABq,J = 9 Hz,9 Hz) EXAMPLE 7 l-(p-methoxyphenyi)-(3S*)-3 1'-[(1'R*)-t-butyldimethyl-silyloxy]-ethyl}-(4r*)-4-(p-chlorobenzoyl)-azetidin- 2-one
A mixture of 553 mg (1 mmol) of the compound prepared in Example 6,0.32 ml (1.2 mmol) oftributyltin hydride and 5 mg of AIBN was refluxed for 4 hours in 40 ml of dry benzene. The cooled reaction mixture was worked up as described in the Example 2 to give a residue which was purified by column chromatography on 20 g of silica gel. Elution with benzene:ethyl acetate 95:5 by volume gave the title compound as a yellow solid (415 mg, 88%).
I.R. (CHCl3, cmi): 1750, 1690, 1590, 1510 N.M.R. (CDCI3, ):-0.35 (3H, s) -0.18 (3H, s) 0.66 (9H, s) 1.28 (3H, d, J = 6 Hz) 3.67 (1H, m,J = 6 Hz) 3.73 (3H, s) 4.15-4.55 (1H, m,J = 6Hz) 5.48(1H,d,J = 6 Hz) 6.70-8.10 (8H, 2 ABq, J = 9Hz, 9 Hz)

Claims (17)

CLAIMS 1. Achiral axetidinone having the general formula
1'R*,3R*,4R* 1'R*,3R*,4S* wherein R1 represents a hydrogen atom or a group which can be replaced by a hydrogen atom in a single step reaction proceeding under mild conditions, R2 represents a hydrogen atom or a hydroxy protecting group, P3 represents a substituted or unsubstituted alkyl or aryl group and R4 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted phenyl group.
2. 1-(p-Methoxyphenyl)-(3R*)-3-{ 1'-[(1'R*)-t-butyldimethyl-silyloxy]-ethyl} -(4R*)-4-acetoxy-azetidine-2-one.
3. (3R*)-3-{ 1'-[(1'R*)-t-Butyidimethyisilyloxy]-ethyl }-(4R*)-4-acetoxy-azetidin-2-one.
4. ' A chiral azetidinone having the general formula Ill
1'R*,3R*,4S* wherein R1, R2 and P3 are as defined in claim 1, X represents a halogen atom and A represents an organic group.
5. A chiral azetidinone according to claim 4wherein A represents: (i) a carboxy group, (ii) a group of the general formula COOR6 wherein P6 represents a carboxy protecting group, (iii) a group of the general formula COR4 wherein R4 is as defined in claim 1, or (iv) a group of the general formula R7 wherein R7 represents a straight or branched chain substituted or unsubstituted alkyl group, a substituted or unsubstituted mono-, di- ortriphenylmethyl group, an alkoxy or aryloxy group; and alkylthio or arylthio group; a protected acyl group, for example phenyl-ethylidene or substituted phenylethylidene; and a group of the general formula
wherein R4 is as above defined.
6. 1 -(p-methoxyphenyl)-(3R*)-3-bromo-3-{1 '-[(1 R*)-t-butyldimethylsilyloxy]-ethyl} -(4S*)-4- methoxycarbonyl-azetidin-2-one.
7. 1-(p-methoxyphenyl)-(3R*)-bromo-3-{ 1 '-[(1 'R*)-t-butyl-dimethylsilyloxy]-ethyl}-(4S*)-4-p- chlorobenzoyl)-azetidin-2-one.
8. A chiral azetidinone having the general formula VI
1'R*,3S*,4R* wherein R1, R2 and P3 are as defined in claim 1 and A is as defined in claim 4.
9. A chiral azetidinone according to claim 8 wherein A represents a carboxy group or a group of the general formula COR4 wherein R4 is as defined in claim 1.
10. 1 -(p-methoxyphenyl)-(3P*)-3-f 1 '-[(1 'R*)-t-butyidimethylsilyloxy]-ethyl } -(4R*)-4-methoxy-carbonyl- azetidin-2-one.
11. 1 -(p-methoxyphenyl)-(3R+)-3-( 1 '-[(1 'R*)-t-butydimethylsilyloxy]-ethyl} -(4R*)-4-carboxy-azetidin-2- one.
12. 1 -(p-methoxyphenyl )-(3S*)-3-{1 '-[(1 'R*)-t-butyldimethylsilyloxy[-ethyl}-(4R*)-4-(p-chlorobenzoyl)- azetidin-2-one.
13. Achiral azetidinone having the general formula VII
lsR*,3st,4st 1'R*,3S*,4R* wherein P1, R2, R3 and R4 are as defined in claim 1 and X is as defined in claim 4.
14. A process for the preparation of a chiral azetidinone according to claim 1, the process comprising reacting in an organic solvent in the presence of a base a chiral a-haloketene having the general formula IV
R,S wherein R2 represents a hydroxy protecting group, P3 represents a substituted or unsubstituted alkyl or aryl group and X represents a halogen atom, or a precursor thereof having the general formula IVa
2R*,3R* wherein R2, P3 and X are as defined in this claim and Y represents a halogen atom or a carboxy activating group, with a Schiff base or imine having the general formula V
wherein A represents a group of the formula COOP6, COR4 or R7 as defined in claim 5 and R1 represents a group which can be replaced by a hydrogen atom in a single step reaction proceeding under mild conditions to obtain a compound of the general formula Ill
1'R*,3R*,4S* wherein R1, R2, R3, X and A are as defined in this claim, and submitting the compound Ill to the following steps:: (i) if A does not represent a group of the formula COR4 then converting it to such a group or to a carboxy group, (ii) oxidatively degrading the group A, (iii) reductively dehalogenating the compound to remove the 3-halo substituent X, (iv) optionally converting the group R1 to a hydrogen atom, and (v) optionally converting the group R2 to a hydrogen atom, the reactions being carried out in any order save that if step (i) is necessary then it must be carried out before step (ii).
15. A process according to claim 14 in which step (ii) is carried out on a compound in which A represents a carboxy group by reacting the compound with at least one mole equivalent of lead tetracetate in an inert solvent.
16. A process according to claim 14 in which step (ii) is carried out on a compound in which A represents a group of the formula COR4 by a Baeyer-Villiger reaction.
17. A process according to claim 14, the process being substantially as described herein with reference to Examples 1 to 4 or Examples 1 to 5.
GB08419149A 1983-08-04 1984-07-27 Azetidinones Expired GB2144419B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838321004A GB8321004D0 (en) 1983-08-04 1983-08-04 Azetidinones

Publications (3)

Publication Number Publication Date
GB8419149D0 GB8419149D0 (en) 1984-08-30
GB2144419A true GB2144419A (en) 1985-03-06
GB2144419B GB2144419B (en) 1987-11-25

Family

ID=10546786

Family Applications (2)

Application Number Title Priority Date Filing Date
GB838321004A Pending GB8321004D0 (en) 1983-08-04 1983-08-04 Azetidinones
GB08419149A Expired GB2144419B (en) 1983-08-04 1984-07-27 Azetidinones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB838321004A Pending GB8321004D0 (en) 1983-08-04 1983-08-04 Azetidinones

Country Status (4)

Country Link
JP (1) JPS6054358A (en)
BE (1) BE900275A (en)
DE (1) DE3428049A1 (en)
GB (2) GB8321004D0 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000615A1 (en) * 1984-07-13 1986-01-30 Sanraku Incorporated New 2-oxoazetidines, process for the preparation and utilization thereof
EP0247378A1 (en) * 1986-04-30 1987-12-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives
EP0269236A1 (en) * 1986-10-24 1988-06-01 Merck & Co. Inc. Process for synthesis of a chiral azetidinone
EP0290385A1 (en) * 1987-05-04 1988-11-09 Ciba-Geigy Ag Process for preparing 4-acyloxy-3-hydroxyethyl-azetidinones
US4791198A (en) * 1984-07-05 1988-12-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Beta-lactam compound and preparation thereof
US4861877A (en) * 1984-07-05 1989-08-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US4882429A (en) * 1986-03-03 1989-11-21 Schering Corporation Stereospecific preparation of (3S,4R,5R)-3-(1-hydroxyethyl)-4-benzoyloxy-azeridinones from L-(-)-theonine
US5043440A (en) * 1986-10-15 1991-08-27 Farmitalia Carlo Erba S.P.A. Oxidation process for preparing 4-acyloxy azetidinones in a two-phase system
US5075439A (en) * 1990-08-17 1991-12-24 Pfizer Inc. Processes for (3S,4R)-3-[1(R)-t-butyl-dimethylsilyloxy)-ethyl]-4-[1-oxo-3-thiolanylthio(thiocarbonyl)thio]azetidin-2-ones and intermediates therefor
GB2252769A (en) * 1991-01-18 1992-08-19 Pfizer Improved process for azetidin-2-ones and intermediates therefor
US5145957A (en) * 1988-03-18 1992-09-08 Merck & Co., Inc. Stereoselective synthesis of a chiral cis 3-beta hydrogen (3R) 4-aroyloxy azetidinone
US5274188A (en) * 1987-05-04 1993-12-28 Ciba-Geigy Corporation Process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones
WO2014097257A1 (en) 2012-12-21 2014-06-26 Instytut Chemii Organicznej Pan A method of preparation of (1'r,3r,4r)-4-acetoxy-3-(1'-(tert-butyldimethylsilyloxy)ethyl)-2-azetidinone, a precursor for carbapenem antibiotics synthesis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2604794B2 (en) * 1988-04-04 1997-04-30 鐘淵化学工業株式会社 Method for producing 4-acetoxy-3-hydroxyethylazetidin-2-one
JP2608458B2 (en) * 1988-05-19 1997-05-07 日本曹達株式会社 Method for producing 4-acetoxyazetidinone derivative
JPH0565291A (en) * 1990-08-17 1993-03-19 Pfizer Inc (3s,4r)-3-(1(r)-(t-butyldimethylsilyloxy)ethyl)-4- (1-oxo-3-thiolanylthio)thiocarbonyl)azetidin-2-ones and improved process for producing their intermediates
KR100205768B1 (en) * 1996-08-24 1999-07-01 Choongwae Pharm Co Stereo-selective composition of 4-acetoxyazetidinone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048261A (en) * 1979-04-11 1980-12-10 Sankyo Co Penem-3-carboxylic acid derivatives, their preparation and use
EP0078026A2 (en) * 1981-10-23 1983-05-04 Merck & Co. Inc. Antibiotic synthesis
EP0070204B1 (en) * 1981-07-15 1987-11-19 Sumitomo Pharmaceuticals Company, Limited Carboxylic beta-lactam compounds and the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111463A (en) * 1979-02-21 1980-08-28 Sankyo Co Ltd Beta-lactam compound and its preparation
JPS56142259A (en) * 1980-03-11 1981-11-06 Sankyo Co Ltd Beta-lactam compound and its preparation
JPS5798257A (en) * 1980-12-10 1982-06-18 Sankyo Co Ltd 3,4-disubstituted azetidine-2-one compound and its preparation
JPS58103358A (en) * 1981-10-23 1983-06-20 メルク・エンド・カムパニ−・インコ−ポレ−テツド Synthesization of antibiotic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048261A (en) * 1979-04-11 1980-12-10 Sankyo Co Penem-3-carboxylic acid derivatives, their preparation and use
EP0070204B1 (en) * 1981-07-15 1987-11-19 Sumitomo Pharmaceuticals Company, Limited Carboxylic beta-lactam compounds and the preparation thereof
EP0078026A2 (en) * 1981-10-23 1983-05-04 Merck & Co. Inc. Antibiotic synthesis

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861877A (en) * 1984-07-05 1989-08-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives
US5061817A (en) * 1984-07-05 1991-10-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Enolsilyl ether compound
US4791198A (en) * 1984-07-05 1988-12-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Beta-lactam compound and preparation thereof
WO1986000615A1 (en) * 1984-07-13 1986-01-30 Sanraku Incorporated New 2-oxoazetidines, process for the preparation and utilization thereof
US4882429A (en) * 1986-03-03 1989-11-21 Schering Corporation Stereospecific preparation of (3S,4R,5R)-3-(1-hydroxyethyl)-4-benzoyloxy-azeridinones from L-(-)-theonine
AU601180B2 (en) * 1986-04-30 1990-09-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin -2- one derivatives
EP0247378A1 (en) * 1986-04-30 1987-12-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives
US4914200A (en) * 1986-04-30 1990-04-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives
US5043440A (en) * 1986-10-15 1991-08-27 Farmitalia Carlo Erba S.P.A. Oxidation process for preparing 4-acyloxy azetidinones in a two-phase system
EP0269236A1 (en) * 1986-10-24 1988-06-01 Merck & Co. Inc. Process for synthesis of a chiral azetidinone
US4927507A (en) * 1987-05-04 1990-05-22 Ciba-Geigy Corporation Novel process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones
EP0290385A1 (en) * 1987-05-04 1988-11-09 Ciba-Geigy Ag Process for preparing 4-acyloxy-3-hydroxyethyl-azetidinones
US5064761A (en) * 1987-05-04 1991-11-12 Ciba-Geigy Corporation Process for the manufacture of 4-acylamino-3-hydroxybutyric acid esters
US5274188A (en) * 1987-05-04 1993-12-28 Ciba-Geigy Corporation Process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones
US5463047A (en) * 1987-05-04 1995-10-31 Ciba-Geigy Corporation Intermediates for the manufacture of 4-acyloxy-3-hydroxyethylazetidinones
US5145957A (en) * 1988-03-18 1992-09-08 Merck & Co., Inc. Stereoselective synthesis of a chiral cis 3-beta hydrogen (3R) 4-aroyloxy azetidinone
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5075439A (en) * 1990-08-17 1991-12-24 Pfizer Inc. Processes for (3S,4R)-3-[1(R)-t-butyl-dimethylsilyloxy)-ethyl]-4-[1-oxo-3-thiolanylthio(thiocarbonyl)thio]azetidin-2-ones and intermediates therefor
GB2252769A (en) * 1991-01-18 1992-08-19 Pfizer Improved process for azetidin-2-ones and intermediates therefor
WO2014097257A1 (en) 2012-12-21 2014-06-26 Instytut Chemii Organicznej Pan A method of preparation of (1'r,3r,4r)-4-acetoxy-3-(1'-(tert-butyldimethylsilyloxy)ethyl)-2-azetidinone, a precursor for carbapenem antibiotics synthesis

Also Published As

Publication number Publication date
DE3428049A1 (en) 1985-02-21
GB8321004D0 (en) 1983-09-07
GB2144419B (en) 1987-11-25
JPH0557980B2 (en) 1993-08-25
DE3428049C2 (en) 1989-09-28
BE900275A (en) 1985-02-01
JPS6054358A (en) 1985-03-28
GB8419149D0 (en) 1984-08-30

Similar Documents

Publication Publication Date Title
GB2144419A (en) Azetidinones
US5300638A (en) Asymmetric synthesis of taxol side chain
FI83521C (en) FOERFARANDE FOER FRAMSTAELLNING AV PENEMER.
HU189559B (en) Process for preparing 2-penem compounds
EP0167155B1 (en) Beta-lactam compound and preparing thereof
US4639335A (en) Stereocontrolled acetoxyazetidinone process
US4508649A (en) Process for preparing optically active penems
KR890004560B1 (en) Process for penem intermediates
EP0283253B1 (en) Method for preparation of azetidinone-1-oxoacetate by oxidation of the corresponding 2-hydroxyacetate
Kita et al. Chemistry of O-silylated ketene acetals: an efficient synthesis of carbapenem and 1β-methylcarbapenem intermediates
GB2162840A (en) Sterospecific process for preparing azetidinones
EP0466509B1 (en) Heterocyclic derivatives
US4767853A (en) Synthesis of 1-(allyloxycarbonyl)-methyl-3-(hydroxyethyl)-4-beta-naphthoxythiocarbonylthio-2-azetidinones and hydroxy protected analogs thereof
US5075439A (en) Processes for (3S,4R)-3-[1(R)-t-butyl-dimethylsilyloxy)-ethyl]-4-[1-oxo-3-thiolanylthio(thiocarbonyl)thio]azetidin-2-ones and intermediates therefor
EP0229384B1 (en) Beta-lactam compounds and their production
KR20040099963A (en) Chiral 2-azetidinone compounds, process and use thereof
JP2810731B2 (en) Production method of β-lactam compound
JPS6363655A (en) Manufacture of optically active beta-lactam
US4554103A (en) Preparation of 4-acyloxyazetidinones from acyl nitrates and penams
CS253736B2 (en) Process for the stereospecific controlled preparation of derivatives of penicillanic acid
GB2166435A (en) 2-modified penams, their preparation and their use
IE910495A1 (en) IMPROVED PROCESSES FOR¹(3S&#39;4R)-3-[1(R)-(t-BUTYLDIMETHYLSILYLOXY)ETHYL]-4-[1-OXO-3-¹THIOLANYLTHIO(THIOCARBONYL)THIO]-AZETIDIN-2-ONES AND¹INTERMEDIATES THEREFOR
EP0521018A1 (en) Process for preparing penem esters
GB2114132A (en) Azetidinone derivatives
JPH07242609A (en) New amino acid derivative

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940727